UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 376

Sortiert nach

Apathy and Depression in Huntington’s Disease: Distinct Longitudinal Trajectories and Clinical Correlates

The journal of neuropsychiatry and clinical neurosciences, 2023-01, Vol.35 (1), p.69-76

2023

Link zum Volltext

Verfügbarkeit prüfen

Agmatine mitigates behavioral abnormalities and neurochemical dysregulation associated with 3-Nitropropionic acid-induced Huntington's disease in rats

Neurotoxicology (Park Forest South), 2024-05, Vol.102, p.12-28

2024

Link zum Volltext

Verfügbarkeit prüfen

Secukinumab treatment for ankylosing spondylitis and concomitant Huntington's disease: real-world experience

Clinical and experimental rheumatology, 2024-03, Vol.42 (3), p.767

2024

Link zum Volltext

Verfügbarkeit prüfen

Combination therapy with Coenzyme Q₁₀ and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's Diseases

Journal of neurochemistry, 2009-06, Vol.109 (5), p.1427-1439

2009

Link zum Volltext

Verfügbarkeit prüfen

TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31

Human molecular genetics, 2018-08, Vol.27 (16), p.2893-2912

2018

Link zum Volltext

Verfügbarkeit prüfen

Alternative Approaches for the Management of Huntington's Disease: A Narrative Review

Alternative therapies in health and medicine, 2024-02, Vol.30 (2), p.68

2024

Link zum Volltext

Verfügbarkeit prüfen

Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin―proteasomal and autophagy systems

Human molecular genetics, 2012-12, Vol.21 (24), p.5280-5293

2012

Link zum Volltext

Verfügbarkeit prüfen

Apoptosis and Caspases in Neurodegenerative Diseases

The New England journal of medicine, 2003-04, Vol.348 (14), p.1365-1375

Friedlander, Robert M

2003

Link zum Volltext

Verfügbarkeit prüfen

Allosteric activation of M₄ muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice

Proceedings of the National Academy of Sciences - PNAS, 2015-11, Vol.112 (45), p.14078-14083

2015

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington’s Disease: Results From the ARC-HD Open-label Study

CNS spectrums, 2021-04, Vol.26 (2), p.164-165

2021

Link zum Volltext

Verfügbarkeit prüfen

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG

Neurology, 2006-01, Vol.66 (2), p.250

2006

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease

The Journal of neuroscience, 2002-03, Vol.22 (5), p.1592-1599

2002

Link zum Volltext

Verfügbarkeit prüfen

Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease

Human molecular genetics, 2018-07, Vol.27 (14), p.2490-2501

2018

Link zum Volltext

Verfügbarkeit prüfen

Chorea

Continuum (Minneapolis, Minn.), 2019-08, Vol.25 (4), p.1001

Termsarasab, Pichet

2019

Link zum Volltext

Verfügbarkeit prüfen

Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data

Expert opinion on pharmacotherapy, 2019-12, Vol.20 (18), p.2209-2221

2019

Link zum Volltext

Verfügbarkeit prüfen

Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs

BMJ open, 2022-06, Vol.12 (6), p.e062740-e062740

2022

Link zum Volltext

Verfügbarkeit prüfen

The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ

EBioMedicine, 2024-05, Vol.103, p.105124-105124, Article 105124

2024

Link zum Volltext

Verfügbarkeit prüfen

Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies

Handbook of experimental pharmacology, 2011 (200), p.267

2011

Link zum Volltext

Verfügbarkeit prüfen

Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects

Movement disorders, 2010-09, Vol.25 (12), p.1924-1928

2010

Link zum Volltext

Verfügbarkeit prüfen

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases

Translational psychiatry, 2013-12, Vol.3 (12), p.e332-e332

2013

Link zum Volltext

Verfügbarkeit prüfen

Adenosine A 1 receptor agonist, N6-cyclohexyladenosine, attenuates Huntington's disease via stimulation of TrKB/PI3K/Akt/CREB/BDNF pathway in 3-nitropropionic acid rat model

Chemico-biological interactions, 2023-01, Vol.369, p.110288

2023

Link zum Volltext

Verfügbarkeit prüfen

A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice

Human molecular genetics, 2016-11, Vol.25 (22), p.4920-4938

2016

Link zum Volltext

Verfügbarkeit prüfen

Cause or compensation?-Altered neuronal Ca 2+ handling in Huntington's disease

CNS neuroscience & therapeutics, 2018-04, Vol.24 (4), p.301-310

2018

Link zum Volltext

Verfügbarkeit prüfen

Tauroursodeoxycholic Acid, A Bile Acid, is Neuroprotective in a Transgenic Animal Model of Huntington's Disease

Proceedings of the National Academy of Sciences - PNAS, 2002-08, Vol.99 (16), p.10671-10676

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 376

Suche als RSS-Feed

Aktive Filter

SprachePortugiesisch

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(246)
Mit Volltextzugriff
(167)

Publikationsform

Sprache

10 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(315)
Huntington Disease - Drug Therapy
(249)
Male
(117)
Female
(107)
Animals
(103)
Middle Aged
(88)
Adult
(87)
Huntington Disease - Metabolism
(61)
Huntington's Disease
(57)
Aged
(53)
Huntington Disease - Physiopathology
(46)
Disease Models, Animal
(44)
Parkinson Disease - Drug Therapy
(44)
Huntington Disease - Genetics
(41)
Mice
(40)
Huntingtons Disease
(35)
Drug Therapy
(31)
Clinical Trials As Topic
(28)
Huntington Disease - Complications
(27)
Huntington Disease - Diagnosis
(27)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Apathy and Depression in Huntington’s Disease: Distinct Longitudinal Trajectories and Clinical Correlates

Agmatine mitigates behavioral abnormalities and neurochemical dysregulation associated with 3-Nitropropionic acid-induced Huntington's disease in rats

Secukinumab treatment for ankylosing spondylitis and concomitant Huntington's disease: real-world experience

Combination therapy with Coenzyme Q₁₀ and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's Diseases

Treatment with THI, an inhibitor of sphingosine-1-phosphate lyase, modulates glycosphingolipid metabolism and results therapeutically effective in experimental models of Huntington’s disease

TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31

Alternative Approaches for the Management of Huntington's Disease: A Narrative Review

Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin―proteasomal and autophagy systems

Apoptosis and Caspases in Neurodegenerative Diseases

Allosteric activation of M₄ muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice

Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington’s Disease: Results From the ARC-HD Open-label Study

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG

Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease

Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease

Chorea

Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data

Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs

The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ

Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies

Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases

Adenosine A 1 receptor agonist, N6-cyclohexyladenosine, attenuates Huntington's disease via stimulation of TrKB/PI3K/Akt/CREB/BDNF pathway in 3-nitropropionic acid rat model

A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice

Cause or compensation?-Altered neuronal Ca 2+ handling in Huntington's disease

Tauroursodeoxycholic Acid, A Bile Acid, is Neuroprotective in a Transgenic Animal Model of Huntington's Disease

Aktive Filter

Suchergebnisse filtern